Abstract
Generally, dialysis patients are under potential risk for iron deficiency because they lose a small amount of blood during every hemodialysis session. Iron deficiency is a major cause of anemia that is resistant to erythropoietin therapy in dialysis patients (1); therefore, iron agents are often administered to dialysis patients, in most cases intravenously. Conversely, aimless continuation of iron administration to dialysis patients sometimes causes iron overload, which is also clearly harmful. Iron overload has been thought to induce the accumulation of iron in the organs and subsequent organ dysfunctions (2). In addition, the risk for immunologic disturbance through reticuloendoplasmic suppression (3) and the promotion of atherosclerosis through the induction of oxidative stress (4) were recently suggested. Thus, the total amount of iron storage in dialysis patients should be controlled to within a certain physiologic range. A precise marker with which to monitor iron …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Clinical Journal of the American Society of Nephrology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
